The development of drug resistance through reversion
Jan 01 2021 · Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer Clin Cancer Res 23 ( 21 ) ( 2017 ) pp. View Record in Scopus Google Scholar
Get Price
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating
Results Diverse and often polyclonal putative BRCA1or BRCA2reversion mutations were identified in cfDNA from four patients with ovarian cancer (21 ) and from two patients with breast cancer (40 ).
Get Price
BRCA Reversion Mutations in Circulating Tumor DNA
Reversion mutations in multiple HRR pathway genes includ-ing BRCA1 BRCA2 RAD51C RAD51D and PALB2 have been reported in ovarian prostate and breast carcinomas as a mechanism of acquired resistance to platinum-based chemo-therapies and PARP inhibitors (13–18). Recent studies have identified somatic reversion BRCA
Get Price
PARP Inhibitor Resistance A Tug-of-War in BRCA-Mutated
Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 2017 23
Get Price
BRCA Reversion Mutations in Circulating Tumor DNA Predict
Feb 01 2019 · The acquired BRCA1 reversion mutations were found within and outside of exon 11 of BRCA1 whereas the BRCA2 reversion mutations were all outside of exon 11 of BRCA2 (Supplementary Fig. S4). The primary BRCA mutations for all eight of these cases were germline in origin (Supplementary Table S1).
Get Price
BRCA1/2 testing therapeutic implications for breast
Jun 05 2018 · Germline mutations in BRCA1 or BRCA2 (gBRCA1/2m) confer a well-established increased risk for the development of papillary serous ovarian cancer (OC) triple-negative breast cancer (TNBC BRCA1
Get Price
The Role of PARP Inhibitors in Germline BRCA-Associated
A study by Christie and colleagues in patients with high-grade serous ovarian cancer found that ctDNA monitoring to identify reversion of germline BRCA1/2 mutations was able to predict treatment responses. 81 Another study used ctDNA to monitor for secondary somatic mutations in patients with germline BRCA -mutated ovarian cancer and was able to predict resistance to platinum-based chemotherapy and
Get Price
(PDF) BRCA Reversion Mutations in Circulating Tumor DNA
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma et al. Diverse BRCA1 and BRCA2
Get Price
The dynamic landscape of BRCA1 reversion mutations from
May 01 2020 · B. Weigelt et al.Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer Clin. Canc. Res. 23 (21) (2017) pp. View Record in Scopus Google Scholar
Get Price
675Gene ResultBRCA2 BRCA2 DNA repair associated (human)
Apr 06 2021 · Inherited mutations in BRCA1 and this gene BRCA2 confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11 which harbors the most important and frequent mutations in breast
Get Price
BRCA1/2 testing therapeutic implications for breast
Jun 05 2018 · Germline mutations in BRCA1 or BRCA2 (gBRCA1/2m) confer a well-established increased risk for the development of papillary serous ovarian cancer (OC) triple-negative breast cancer (TNBC BRCA1
Get Price
Reversion of BRCA1/2 Germline Mutations Detected in
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer Elizabeth L. Christie Sian Fereday Ken Doig Swetansu Pattnaik Sarah-Jane Dawson and David D.L. Bowtell ABSTRACT Purpose Germline BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are
Get Price
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating
Request PDF Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer Purpose Resistance to
Get Price
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating
Request PDF Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer Purpose Resistance to
Get Price
BRCA Reversion Mutations in Circulating Tumor DNA Predict
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC) we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from
Get Price
Potential clinical applications of circulating cell-free
Weigelt B et al. (2017) Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clinical Cancer Research 23 . 95.
Get PricePotential clinical applications of circulating cell-free
Weigelt B et al. (2017) Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clinical Cancer Research 23 . 95.
Get PriceOlaparib in hormone receptor-positive HER2-negative
Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res 2017 23 . Google Scholar Crossref Medline
Get Price
Polyclonal BRCA2 Reversion Mutations Detected in
Recently reversion mutations to restore BRCA1/2 function have been observed in prostate tumors sampled by biopsy and in circulating tumor DNA (ctDNA) from patients who were treated with PARP inhibitors. 10 11 Here we describe a case of a patient with mCRPC who exhibited polyclonal BRCA2 reversion mutations at the time of disease progression
Get Price
VCV.8ClinVarNCBI
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Weigelt B Clinical cancer research an official journal of the American Association for Cancer Research 2017 PMID
Get Price
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating
Aug 01 2017 · Diverse and often polyclonal putative BRCA1 or BRCA2 reversion mutations were identified in cfDNA from four ovarian cancer patients (21 ) and from two breast cancer patients (40 ).
Get PriceVCV.8ClinVarNCBI
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Weigelt B Clinical cancer research an official journal of the American Association for Cancer Research 2017 PMID
Get Price
Reversion and non-reversion mechanisms of resistance to
May 01 2020 · Diverse BRCA1 and BRCA2 Reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer Clin Cancer Res 23 ( 21 ) ( 2017 ) pp. View Record in Scopus Google Scholar
Get Price
The Role of PARP Inhibitors in Germline BRCA-Associated
A study by Christie and colleagues in patients with high-grade serous ovarian cancer found that ctDNA monitoring to identify reversion of germline BRCA1/2 mutations was able to predict treatment responses. 81 Another study used ctDNA to monitor for secondary somatic mutations in patients with germline BRCA -mutated ovarian cancer and was able to predict resistance to platinum-based chemotherapy and
Get PriceLiquid biopsies for cancer Hype or hope
Weigelt B Comino-Méndez I de Bruijn I Tian L Meisel JL García-Murillas I et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res. 2017 Nov 123(21) 6708–20.
Get PriceRucaparib Monotherapy in Patients With Pancreatic Cancer
May 16 2018 · Weigelt B Comino-Méndez I de Bruijn I et al Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res 23 2017 Crossref Medline Google Scholar 26.
Get Price
Resistance Mechanisms OncologyPRO
Weigelt B Comino-Mendez I de Bruijn I et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 2017 23
Get PriceDiverse BRCA1 and BRCA2 ReversionMutationsin Circulating
Results Diverse and often polyclonal putative BRCA1 or BRCA2 reversion mutations were identified in cfDNA from four patients with ovarian cancer (21 ) and from two patients with breast cancer (40 ).
Get PriceRoutine Plasma-Based Genotyping to Comprehensively Detect
Polyclonal reversion mutations (median 5) were detected in 9 of 42 (21.4 ) germline BRCA1/2- mutant patients the majority (77.7 ) of whom had prior PARPi exposure (median duration 10 months).
Get Price
Secondary BRCA1 and BRCA2 alterations and acquired
Jul 01 2008 · Tumor suppressor BRCA1 and BRCA2 are frequently mutated in familial breast and ovarian cancer. More than ten percent of women with breast or ovarian cancer carry BRCA1 or BRCA2 (BRCA1/2) mutations.Cancers that arise in mutation carriers have often lost the wild-type allele through somatic alterations during tumor progression 1 2 .BRCA1/2 play important roles in homologous
Get Price
